Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

NCT03172624 PHASE2 COMPLETED Results posted

The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	PHASE2
Status	COMPLETED
Enrolment	64
Start date	Fri May 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Salivary Gland Cancer

Interventions

• Nivolumab
• Ipilimumab

Countries

United States